Jialei Wang

6PUBLICATIONS
25CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 09, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Jhanelle E Gray, Konstantin Laktionov, Sang-We Kim

|Jan 20, 2025
EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAFV600E mutation: a multi-center real-world experience in China.

Wenyue Yang, Xiangran Feng, Jian Ni

|Mar 27, 2024
Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.

Yao Zhang, Huiting Li, Bo Yu

|Apr 04, 2023
Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.

Jiatao Liao, Hongyan Lai, Chang Liu

|Apr 07, 2022
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.

Chang Liu, Jiatao Liao, Xianghua Wu

|Apr 13, 2019
Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.

Chang Liu, Hui Yu, Jianhua Chang

Pageof 1

Frequent Collaborators

1 joint publications

Yan Li

1 joint publications

Ying Lin

1 joint publications

Yao Zhang

1 joint publications

Zhihuang Hu